Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06567899

Mechanistic Underpinnings of Preeclampsia

Preeclampsia is a dreadful disease with significant morbidity and mortality. Despite decades of research, we still need a proper diagnostic test or therapeutic option to treat this disorder. The proposed study will determine the diagnostic value of PBMC-secreted sFlt1 and determine the molecular mechanisms involved in its secretion. The molecular mechanisms can be novel therapeutic targets to treat this disorder.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Healthy Adults:

  • Healthy non-pregnant with previous normal pregnant women

Non-Health Adults:

  • Patients will be admitted with the diagnosis of preeclampsia according to the internationally accepted definition of preeclampsia: Blood pressure measurement of 140/90 mm Hg or an increase of 30 mm Hg systolic or 15 mm Hg diastolic over baseline values on at least two occasions, six or more hours apart and proteinuria; 300 mg/24 hour after 20th week of gestation.

Pregnant Women:

Groups 3 - 6 will include pregnant women at different trimesters.

Criteria common to all groups:

  • The study will be conducted only in females aged 18 or above.
  • Patients in all the groups will be matched for age, which will be 18 or above.
  • Women will be matched for body mass index; criteria for normal body mass index will be used based on the Center for Disease Control and Prevention Guidelines.
  • Patients with premature rupture of the membrane, non-preeclamptic preterm labor, IUGR, placental abruption, twin? Any other complications during the pregnancy will be excluded from the study.
  • Patients with any evidence of genetic or non-genetic malformations of the fetus will be excluded from the study.
  • The study will be conducted on women who are non-smokers and do not consume alcohol or recreational drugs.
  • The study will be conducted only on primigravida females to minimize phenotyping variability.
  • The women with a known history of any chronic disorder, including but not limited to hypertension, diabetes, pulmonary, renal, cardiac, or cerebrovascular disorders, will be excluded from the studies.

Treatment and study plan

Primary outcomes

  1. sFLT1 levels

    Time frame: Outcome will be measured at 12 weeks, 24 weeks and 36 weeks of pregnancy.

    sFLT1 levels in preeclampsia should be higher than normal pregnancy.

Study contacts

Contact information is provided by the study sponsor or research team.

Ravi Goyal, MD, PhD

CONTACT

[email protected]

520-626-5573

Sponsors and collaborators

Lead sponsor

University of Arizona

Other

Registry information

Acronym: MUP

Important dates

Study start
2026
Primary completion
2027
Study completion
2029
First posted
Aug 23, 2024
Registry last updated
Nov 26, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.